我是 LongbridgeAI，我可以總結文章信息。Star Sports Medicine Co. Ltd.在首次公開募股（IPO）中表現出色，股價在交易開始時上漲三倍，最終在午盤時上漲 132%。該公司以每股 98.50 港元出售了 842 萬股，籌集淨收益為 7.58 億港元（9700 萬美元）。香港本地投資者的公開發售超額認購超過 7800 倍，國際發售則超額認購 9.4 倍。Star Sports Medicine 是中國第四大運動醫學植入物和設備供應商，預計在 2024 年佔有約 6.5% 的市場份額。
Shares of medical device company Star Sports Medicine Co. Ltd. (1609.HK) tripled from their IPO price when trading began on Tuesday, before giving back some of the gains to close up 132% at the midday break.
The company sold 8.42 million shares for HK$98.50 each, raising net proceeds of HK$758 million ($97 million). The public offering for local Hong Kong investors was more than 7,800 times oversubscribed, while the international offering was oversubscribed by 9.4 times.
Star Sports Medicine is China’s fourth-largest provider of sports medicine implants and devices, controlling about 6.5% of the market in 2024. The company’s revenue reached 403 million yuan ($59 million) last year, up 23% year-on-year, while its profit jumped 44% to 137 million yuan.
The company plans to use 30% of the IPO proceeds to expand its production capabilities and efficiency. Another 35% will go to R&D, 25% to commercialization, sales, and marketing, and the remaining 10% to general working capital.
By Lau Chi Hang
To subscribe to Bamboo Works weekly free newsletter, click here